Johanna T. W. Snijkers

Johanna T. W. Snijkers

Auto-generated profile, based on publicly available information

Johanna T. W. Snijkers

Department of Gastroenterology and Hepatology Maastricht University Medical Centre+ Maastricht the Netherlands

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
ZWZsa Zsa Weerts
Zsa Zsa Weerts
AMAd A.M. Masclee
Ad A.M. Masclee
BWBen J.M. Witteman
Ben J.M. Witteman
CCCees H.M. Clemens
Cees H.M. Clemens
Bjorn WinkensBjorn Winkens
Bjorn Winkens
DKDaniel Keszthelyi
Daniel Keszthelyi

3 May 2021 in Neurogastroenterology & Motility
Verified
Journal Article
Open access
PDF file
JSJohanna T. W. Snijkers
Johanna T. W. Snijkers
WOWendy van Den Oever
Wendy van Den Oever
ZWZsa Zsa Weerts
Zsa Zsa Weerts
LVLisa Vork
Lisa Vork
ZMZlatan Mujagic
Zlatan Mujagic
DKDaniel Keszthelyi
Daniel Keszthelyi
Background: Self‐rating scales are frequently used to screen for anxiety and depression in patients with irritable bowel syndrome (IBS). Different cutoff values are recommended in literature, and guidelines have suggested the use of other screening instruments over time. The aim of this study was to assess the correlation between the most commonly used psychological screening instruments for anxiety and depression in IBS and to compare custom cutoff scores for these instruments.Methods: Irritable bowel syndrome patients (n = 192) completed several questionnaires including the Hospital Anxiety and Depression Scale (HADS, HADS‐A and HADS‐D subscale), Patient Health Questionnaire‐9 (PHQ‐9) and Generalized Anxiety Disorder‐7 (GAD‐7). Agreement at different cutoff points, for depressive and anxiety disorder, was assessed by use of the Gwet AC1 coefficient.Key Results: Hospital Anxiety and Depression Scale (HADS)‐D and PHQ‐9 scores, and HADS‐A and GAD‐7 scores showed high correlations (rs = 0.735 and rs = 0.805, respectively). For depressive disorder, a Gwet AC1 value of 0.829 was found when recommended cutoff points from literature were compared (PHQ‐9 cutoff ≥10, HADS‐D cutoff ≥8). For anxiety disorder, a Gwet AC1 value of 0.806 was found when recommended cutoff points from literature were compared (GAD‐7 cutoff ≥10, HADS‐A cutoff ≥8). Even higher agreements were found when higher HADS cutoff values were chosen, with impact on sensitivity and specificity.Conclusions & Inferences: Custom cutoff values deem the HADS subscales (HADS‐D and HADS‐A) concordant to PHQ‐9 and GAD‐7 scores. The choice of a cutoff value has substantial impact on sensitivity/specificity and is dependent on patient population, setting, and the purpose of use.

4 October 2023 in American Journal of Gastroenterology
Verified
Journal Article
Open access
JSJohanna T.W. Snijkers
Johanna T.W. Snijkers
Bjorn WinkensBjorn Winkens
Bjorn Winkens
ZWZsa Zsa Weerts
Zsa Zsa Weerts
LVLisa Vork
Lisa Vork
ZMZlatan Mujagic
Zlatan Mujagic
DKDaniel Keszthelyi
Daniel Keszthelyi
INTRODUCTION: Irritable bowel syndrome (IBS) has a major impact on emotional, social, and professional life. This study aimed to evaluate general life satisfaction, a subjective measure of well-being, in IBS patients, and to determine which factors are associated with higher life satisfaction. METHODS: IBS patients (n = 195, mean age 51.4 ± 16.5 years, 73.8% female) recruited from primary and secondary/tertiary care completed questionnaires regarding gastrointestinal symptoms, quality of life, psychological factors, and life satisfaction (Satisfaction With Life Scale, 5 items, range 5–35). A finite mixture model analysis was performed to identify latent classes. Multivariable linear regression was used to identify variables associated with life satisfaction. RESULTS: Overall, 71.3% of the patients were satisfied about their life (Satisfaction With Life Scale-score ≥21). Three latent subgroups could be identified with significantly higher life satisfaction in the subgroup with higher mental quality of life, fewer anxiety and depressive symptoms, lower gastrointestinal specific anxiety, and lower gastrointestinal symptom severity, compared with the other 2 groups. Multivariable linear regression showed that higher physical quality of life (B0.168, P < 0.001) and higher mental quality of life (B0.199, P < 0.001) were associated with higher life satisfaction. Using multivariable regression, no significant association was found between gastrointestinal symptom severity and life satisfaction. DISCUSSION: Higher physical and mental quality of life, but not gastrointestinal symptom severity, were independently associated with higher general life satisfaction in IBS. These findings reinforce the clinical need in IBS treatment to focus on the full extent of the disorder and not merely on gastrointestinal symptom improvement. ClinicalTrials.gov Identifier: NCT00775060.

23 November 2021 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
GMGwen M. C. Masclee
Gwen M. C. Masclee
JSJohanna T. W. Snijkers
Johanna T. W. Snijkers
MBMarijke Boersma
Marijke Boersma
AMA.A.M. Masclee
A.A.M. Masclee
DKDaniel Keszthelyi
Daniel Keszthelyi
Background: Irritable bowel syndrome (IBS) is a highly prevalent disorder with significant negative impact on quality of life of patients that results in high healthcare use and costs. Improving healthcare outcomes for IBS patients is warranted, however the exact needs of IBS patients with regard to therapy and control of symptoms are unknown. Methods: Focus group interviews, using a two-stage model, were performed with twenty-three IBS patients meeting Rome III criteria and one mother of a patient, from four different regions from the Netherlands. Results: Twenty-four participants were included of whom majority were female (n = 21), mean age was 43 years, and mean duration of IBS was 18 years. Five categories of patients’ perspectives were identified: clear communication, a multidisciplinary treatment team, centers of expertise, focus on scientific research and information about IBS that is widely available for patients. Conclusions: Based on these findings we highlight the need for IBS care givers to take these key items into account in IBS care. These elements aid clinicians, but mostly patients, in coping and management of symptoms and subsequent healthcare outcomes, reducing overall healthcare use and costs.

29 January 2026 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Open access
DBDaan H.C.A. Bosch
Daan H.C.A. Bosch
ABAbraham Beckers
Abraham Beckers
JSJohanna T.W. Snijkers
Johanna T.W. Snijkers
MBMichelle H.M.A. Bosman
Michelle H.M.A. Bosman
Bjorn WinkensBjorn Winkens
Bjorn Winkens
DKDaniel Keszthelyi
Daniel Keszthelyi
Low dose tricyclic antidepressants may be effective for patients with functional dyspepsia (FD), although high-quality randomized controlled trials (RCTs) are limited. We aimed to investigate the efficacy of nortriptyline in an escalating low dose regimen vs placebo in participants with FD following a genotype-guided pre-selection based on cytochrome P450 2D6 (CYP2D6), the primary enzyme responsible for nortriptyline metabolism. We conducted a multicenter, RCT of patients with FD in primary, secondary and tertiary care. 69 participants were randomly assigned to nortriptyline (week 1-2: 10mg; week 3-4: 25mg; week 5-12: 50mg) versus placebo for a 12-week treatment. The primary outcome was clinical response based on a decrease in FD symptoms of at least 30% compared to baseline, in 50% of the last 10 weeks of the treatment period. The primary outcome showed no significant difference in response for nortriptyline compared to placebo (45% vs 58%; OR, 0.574; 95% CI, 0.211 to 1.560; p=0.276). There was no significant difference in adverse events between the nortriptyline and placebo group. Nortriptyline plasma levels were significantly higher in responders compared to non-responders (13.0 μg/L; IQR, 12.0-16.0 vs 9.0 μg/L; IQR, 8.0-10.5; p=0.003). The belief to have received nortriptyline showed a higher response rate than the belief to have received placebo (77% vs 36%; OR, 11.439; 95% CI, 2.138 to 61.201; p=0.004). Nortriptyline was not more effective than placebo in reducing FD symptoms in participants pre-selected based on CYP2D6 genotype, although a biological effect of nortriptyline could not be ruled out. However, effects related to participants' belief appeared to be stronger; Clinicaltrials.gov number, NCT03652571.

24 November 2021 in JMIR Formative Research
Verified
Journal Article
Open access
ABAbraham Beckers
Abraham Beckers
JSJohanna T W Snijkers
Johanna T W Snijkers
ZWZsa Zsa Weerts
Zsa Zsa Weerts
LVLisa Vork
Lisa Vork
TKTim Klaassen
Tim Klaassen
DKDaniel Keszthelyi
Daniel Keszthelyi
Background: Questionnaires are necessary tools for assessing symptoms of disorders of the brain-gut interaction in clinical trials. We previously reported on the excellent adherence to a smartphone app used as symptom diary in a randomized clinical trial on irritable bowel syndrome (IBS). Other sampling methods, such as the experience sampling method (ESM), are better equipped to measure symptom variability over time and provide useful information regarding possible symptom triggers, and they are free of ecological and recall bias. The high frequency of measurements, however, could limit the feasibility of ESM in clinical trials. Objective: This study aimed to compare the adherence rates of a smartphone-based end-of-day diary and ESM for symptom assessment in IBS and functional dyspepsia (FD). Methods: Data from 4 separate studies were included. Patients with IBS participated in a randomized controlled trial, which involved a smartphone end-of-day diary for a 2+8-week (pretreatment + treatment) period, and an observational study in which patients completed ESM assessments using a smartphone app for 1 week. Patients with FD participated in a randomized controlled trial, which involved a smartphone end-of-day diary for a 2+12-week (pretreatment + treatment) period, and an observational study in which patients completed ESM assessments using a smartphone app for 1 week. Adherence rates were compared between these 2 symptom sampling methods. Results: In total, 25 patients with IBS and 15 patients with FD were included. Overall adherence rates for the end-of-day diaries were significantly higher than those for ESM (IBS: 92.7% vs 69.8%, FD: 90.1% vs 61.4%, respectively). Conclusions: This study demonstrates excellent adherence rates for smartphone app–based end-of-day diaries as used in 2 separate clinical trials. Overall adherence rates for ESM were significantly lower, rendering it more suitable for intermittent sampling periods rather than continuous sampling during longer clinical trials.